Review: taking Enbrel and Plaquenil together


Summary

Drug interactions are reported among people who take Enbrel and Plaquenil together. This review analyzes the effectiveness and drug interactions between Enbrel and Plaquenil. It is created by eHealthMe based on reports of 9,288 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Enbrel and Plaquenil >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Enbrel

Enbrel has active ingredients of etanercept. It is often used in rheumatoid arthritis. (latest outcomes from Enbrel 257,796 users)

Plaquenil

Plaquenil has active ingredients of hydroxychloroquine sulfate. It is often used in rheumatoid arthritis. (latest outcomes from Plaquenil 19,931 users)

On Aug, 28, 2016

9,288 people who take Enbrel, Plaquenil are studied.


Number of reports submitted per year:

Enbrel and Plaquenil drug interactions.

Drug effectiveness over time:

Enbrel:
  • < 1 month: 50.0% - (3 of 6 people)
  • 1 - 6 months: 41.0% - (5 of 12 people)
  • 6 - 12 months: 66.0% - (4 of 6 people)
  • 1 - 2 years: 100.0% - (5 of 5 people)
  • 2 - 5 years: 37.0% - (3 of 8 people)
  • 5 - 10 years: 57.0% - (4 of 7 people)
  • 10+ years: 100.0% - (1 of 1 people)
  • not specified: 0.0% - (0 of 0 people)
Plaquenil:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 50.0% - (3 of 6 people)
  • 6 - 12 months: 20.0% - (1 of 5 people)
  • 1 - 2 years: 33.0% - (2 of 6 people)
  • 2 - 5 years: 12.0% - (2 of 16 people)
  • 5 - 10 years: 25.0% - (1 of 4 people)
  • 10+ years: 25.0% - (1 of 4 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Enbrel:
  • female: 55.0% - (21 of 38 people)
  • male: 57.0% - (4 of 7 people)
Plaquenil:
  • female: 22.0% - (8 of 35 people)
  • male: 33.0% - (2 of 6 people)

Drug effectiveness by age:

Enbrel:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 50.0% - (1 of 2 people)
  • 30-39: 66.0% - (6 of 9 people)
  • 40-49: 57.0% - (8 of 14 people)
  • 50-59: 46.0% - (7 of 15 people)
  • 60+: 60.0% - (3 of 5 people)
Plaquenil:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 1 people)
  • 30-39: 25.0% - (2 of 8 people)
  • 40-49: 23.0% - (3 of 13 people)
  • 50-59: 28.0% - (4 of 14 people)
  • 60+: 20.0% - (1 of 5 people)

Most common drug interactions over time *:

< 1 month:
  • injection site erythema
  • headache
  • rheumatoid arthritis
  • fatigue
  • injection site pruritus
  • arthralgia
  • asthenia
  • hypersensitivity
  • injection site reaction
  • injection site pain
1 - 6 months:
  • pain
  • drug ineffective
  • arthralgia
  • injection site erythema
  • injection site pain
  • injection site pruritus
  • rheumatoid arthritis
  • pain in extremity
  • headache
  • injection site swelling
6 - 12 months:
  • arthralgia
  • pelvic pain
  • vaginal haemorrhage
  • rheumatoid arthritis
  • pneumonia
  • squamous cell carcinoma of the cervix
  • headache
  • lymphadenopathy
  • nausea
  • cellulitis
1 - 2 years:
  • pain in extremity
  • pneumonia
  • paraesthesia
  • rheumatoid arthritis
  • fatigue
  • urinary tract infection
  • arthralgia
  • pain
  • cellulitis
  • drug ineffective
2 - 5 years:
  • rheumatoid arthritis
  • arthralgia
  • drug ineffective
  • hair loss
  • fatigue
  • pyrexia
  • systemic lupus erythematosus
  • bone and joint pain
  • upper respiratory tract infection
  • headache
5 - 10 years:
  • rheumatoid arthritis
  • arthralgia
  • fatigue
  • nausea
  • fall
  • headache
  • osteoporosis
  • pain in extremity
  • drug ineffective
  • pain
10+ years:
  • pneumonia
  • arthralgia
  • lung neoplasm
  • lymphadenopathy
  • rheumatoid arthritis
  • appendicitis perforated
  • cellulitis
  • escherichia infection
  • ovarian cyst
  • pseudomonas infection
not specified:
  • injection site pain
  • rheumatoid arthritis
  • injection site erythema
  • arthralgia
  • drug ineffective
  • fatigue
  • injection site pruritus
  • injection site swelling
  • nausea
  • headache

Most common drug interactions by gender *:

female:
  • injection site pain
  • rheumatoid arthritis
  • injection site erythema
  • arthralgia
  • fatigue
  • drug ineffective
  • nausea
  • injection site pruritus
  • injection site haemorrhage
  • headache
male:
  • arthralgia
  • rheumatoid arthritis
  • drug ineffective
  • pain
  • injection site pain
  • fatigue
  • pyrexia
  • cough
  • injection site reaction
  • asthenia

Most common drug interactions by age *:

0-1:
  • bladder diverticulum
  • clostridial infection
  • palatal disorder
  • reflux nephropathy
  • renal hypertrophy
  • respiratory syncytial virus infection
  • urinary tract infection
  • congenital cystic kidney disease
  • premature baby
  • chest pain
2-9:
  • psoriasis
  • pain in extremity
  • injection site pain
  • pyrexia
  • alopecia
  • arthralgia
  • back pain
  • c-reactive protein abnormal
  • drug ineffective
  • lymphocyte count abnormal
10-19:
  • injection site pain
  • injection site erythema
  • injection site pruritus
  • nausea
  • clostridial infection
  • hospitalisation
  • abdominal pain
  • drug ineffective
  • injection site haematoma
  • injection site rash
20-29:
  • injection site erythema
  • injection site swelling
  • vaginal haemorrhage
  • pelvic pain
  • injection site pain
  • premature labour
  • anaesthetic complication pulmonary
  • obstructed labour
  • respiratory arrest
  • uterine leiomyoma
30-39:
  • injection site erythema
  • injection site pain
  • injection site haemorrhage
  • injection site pruritus
  • injection site swelling
  • nausea
  • rheumatoid arthritis
  • injection site haematoma
  • injection site reaction
  • headache
40-49:
  • injection site erythema
  • injection site pain
  • rheumatoid arthritis
  • arthralgia
  • injection site haemorrhage
  • headache
  • drug ineffective
  • fatigue
  • injection site swelling
  • nausea
50-59:
  • injection site pain
  • rheumatoid arthritis
  • arthralgia
  • injection site erythema
  • fatigue
  • pain
  • drug ineffective
  • nausea
  • headache
  • sinusitis
60+:
  • rheumatoid arthritis
  • arthralgia
  • injection site pain
  • drug ineffective
  • pain
  • injection site haemorrhage
  • fatigue
  • injection site erythema
  • nausea
  • pain in extremity

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Enbrel and Plaquenil?

Can you answer these questions?

More questions for: Enbrel, Plaquenil

You may be interested in these reviews

More reviews for: Enbrel, Plaquenil

On eHealthMe, Enbrel (etanercept) is often used to treat rheumatoid arthritis. Plaquenil (hydroxychloroquine sulfate) is often used to treat rheumatoid arthritis. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.